Join Angion Biomedica CEO Dr. Jay Venkatesan and FLG partner and CFO Greg Curhan for a fireside chat with Managing Partner Laureen De Buono “Launching an IPO in a Time of Coronavirus: The Story of Angion Biomedica“.
Angion Biomedica is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its investigational drug ANG-3777 has completed enrollment in a phase 3 clinical trials for acute kidney injury following kidney transplant, also known as delayed graft function. ANG-3777 is enrolling a phase 2 trial for cardiac surgery-associated acute kidney injury and a phase 2 trial evaluating the safety and efficacy of ANG-3777 in patients with acute lung injury associated with COVID-19 related pneumonia at high risk of acute respiratory distress syndrome. The company launched its IPO February 5, 2021.
About Our Speakers:
Jay Venkatesan is President and CEO at Angion Biomedica and Managing Partner at Alpine BioVentures. Prior to joining Alpine BioVentures, Dr. Venkatesan was the executive vice president and general manager of Oncothyreon, Inc., which he joined after it was acquired by Alpine Biosciences, where he served as co-founder and CEO. Previously, Dr. Venkatesan was the founder, portfolio manager and managing director of Ayer Capital Management, a global healthcare long-short equity fund. Prior to that, he served as a director at Brookside Capital Partners, the hedge fund group affiliated with Bain Capital, where he co-managed healthcare investments and evaluated public and private investments in all healthcare subsectors. Earlier in his career, Dr. Venkatesan was involved in healthcare venture investing at Patricof & Co. Ventures (now Apax Partners) and consulting at McKinsey & Company. Dr. Venkatesan currently serves on the Board of Directors of Lion Biotechnologies and AuraSense Therapeutics. He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.
Greg Curhan joined FLG in 2020 with 35 plus years of financial, capital markets and strategic advisory experience across diverse sectors including Medical Device and Life Sciences, Investment Banking, Internet and Clean Technology. Greg begin his role as Interim CFO at Angion Biomedica in June 2020 in preparation for the company’s IPO. Prior to FLG, Greg has raised equity and debt capital for Public and Private companies, and has executed M&A transactions on both the buy and sell-side. He has also served in CEO, President and Board of Director capacities. Prior to FLG, Greg was CFO and SVP Corporate Development of Providence Medical Technology. He also founded and was President of Merriman Curhan Ford (an investment bank) from 2002 to 2009, growing it from a pre-revenue startup to a $90 million dollar, profitable public company. Greg was recently appointed to the Advisory Board at Specific Diagnostics.
